GL
Gemina Laboratories Ltd.
GLABF · OTC
$0.05 +0.00% (+$0.00)
Market Cap $5.28M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.07
40.0% upside
Current Price
$0.05
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GLABF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
0 /100
Expensive P/S 245.74x
PEG N/A
P/E N/A
Growth
-
N/A FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Op. margin 9,865.92%
Gross margin 66.01%
FCF margin 2,377.07%
Quality
57 /100
Average Asset turnover 0.01x
ROIC 45.26%
ROA 137.11%
Debt
0 /100
High Int. coverage -27.05x
Current ratio 0.07x
Debt/Assets N/A
Stability
62 /100
Moderate Profitable years 0
Beta -0.07x
EPS volatility 10.93%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GLABF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Robert Crandall Greene
Employees
6
Headquarters
Burnaby